Efficacy and safety of PD1/PDL1 blockade with platinum-based chemotherapy for extensive small cell lung cancer: A pooled analysis of randomized trials

Eur J Clin Invest. 2021 May;51(5):e13483. doi: 10.1111/eci.13483. Epub 2021 Jan 17.

Authors

Carlo Messina¹, Massimiliano Salati², Marco Messina³, Carlo Cattrini^{4

5}, Valeria Merz¹, Orazio Caffo¹

Affiliations

¹ Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
² Department of Medical Oncology, University Hospital of Modena and Reggio Emilia, Modena, Italy.
³ Oncology Unit, Ospedali Riuniti Villa Sofia, Cervello, Italy.
⁴ Division of Oncology, Ospedale Maggiore della Carità, Novara, Italy.
⁵ Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, Genova, Italy.

PMID: 33382454
DOI: 10.1111/eci.13483

No abstract available

Publication types

Letter
Meta-Analysis

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Etoposide / administration & dosage
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Platinum Compounds / administration & dosage
Randomized Controlled Trials as Topic
Small Cell Lung Carcinoma / drug therapy*
Small Cell Lung Carcinoma / pathology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
Platinum Compounds
durvalumab
atezolizumab
Etoposide
pembrolizumab